Videos: Lilly MDR-TB Partnership advances fight in South Africa and Swaziland
In recognition of World TB Day on March 24, Lilly joins with others across the world to advance the fight against TB and multidrug-resistant tuberculosis. In places like Swaziland and Gugulethu, South Africa, The Lilly MDR-TB Partnership is making a difference. See how in these brief videos.
The Lilly MDR-TB Partnership is comprised of more than 25 health organizations, academic institutions and corporations. The goal of the partnership is to combat the expanding global crisis of multidrug-resistant tuberculosis by providing access to medicines, raising awareness and training healthcare professionals.
In 2011, the Lilly Foundation committed an additional $30 million (USD) to help advance the partnership’s efforts in two key areas over the next five years (2012-2016): providing training for healthcare providers and improving access to MDR-TB medicines. The Lilly MDR-TB Partnership works with partners at the global and local level, with a specific focus in China, India, Russia and South Africa – countries with the highest burden of MDR-TB.
Through the work of The Lilly MDR‐TB Partnership, thousands of people across the world are gaining access to the care and support they need to be correctly diagnosed and treated for this curable disease.
About the Lilly Foundation
The Lilly Foundation, which receives its funding from Eli Lilly and Company, was established in 1968 as a tax-exempt private foundation to support philanthropic initiatives in healthcare, education and community development. In the area of healthcare, the Lilly Foundation collaborates with global and local partners to find innovative solutions to complex healthcare challenges.
About Eli Lilly and Company
Eli Lilly and Company, a leading innovation-driven corporation is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Eli Lilly and Company provides answers – through medicines and information – for some of the world's most urgent medical needs.
In October 2011, the Lilly Foundation committed $30 million (USD) in funding to further support The Lilly MDR-TB Partnership in its fight against multidrug-resistant tuberculosis, a disease that disproportionately affects developing countries and kills more than 150,000 people each year. Read Lilly’s press release.
Learn more about The Lilly MDR-TB Partnership here.
Did you know? According to the World Health Organization:
- More than two billion people, equal to one third of the world’s total population, are infected with TB bacilli, the microbes that cause TB. One in every 10 of those people will become sick with active TB in his or her lifetime. People living with HIV are at a much greater risk.
- A total of 1.7 million people died from TB in 2009 (including 380 000 people with HIV), equal to about 4,700 deaths a day. TB is a disease of poverty, affecting mostly young adults in their most productive years. The vast majority of TB deaths are in the developing world, with more than half occurring in Asia.
- There were an estimated 440,000 new MDR‐TB cases in 2008 with three countries accounting for over 50 percent of all cases globally: China, India and the Russian Federation.
- 41 million TB patients have been successfully treated in DOTS programs and up to 6 million lives saved since 1995. Five million more lives could be saved between now and 2015 by fully funding and implementing The Global Plan to Stop TB 2011‐2015.